350 related articles for article (PubMed ID: 20551724)
1. Pain response profile of patients with fibromyalgia treated with duloxetine.
Bradley LA; Wohlreich MM; Wang F; Gaynor PJ; Robinson MJ; D'Souza DN; Mease PJ
Clin J Pain; 2010; 26(6):498-504. PubMed ID: 20551724
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.
Mease PJ; Russell IJ; Kajdasz DK; Wiltse CG; Detke MJ; Wohlreich MM; Walker DJ; Chappell AS
Semin Arthritis Rheum; 2010 Jun; 39(6):454-64. PubMed ID: 19152958
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
[TBL] [Abstract][Full Text] [Related]
5. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia.
Chappell AS; Littlejohn G; Kajdasz DK; Scheinberg M; D'Souza DN; Moldofsky H
Clin J Pain; 2009 Jun; 25(5):365-75. PubMed ID: 19454869
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study.
Arnold LM; Zhang S; Pangallo BA
Clin J Pain; 2012; 28(9):775-81. PubMed ID: 22971669
[TBL] [Abstract][Full Text] [Related]
7. Early improvement in pain predicts pain response at endpoint in patients with fibromyalgia.
Wang F; Ruberg SJ; Gaynor PJ; Heinloth AN; Arnold LM
J Pain; 2011 Oct; 12(10):1088-94. PubMed ID: 21763211
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
Russell JM; Weisberg R; Fava M; Hartford JT; Erickson JS; D'Souza DN
Depress Anxiety; 2008; 25(7):E1-11. PubMed ID: 17587217
[TBL] [Abstract][Full Text] [Related]
9. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
Brannan SK; Mallinckrodt CH; Detke MJ; Watkin JG; Tollefson GD
J Psychiatr Res; 2005 Mar; 39(2):161-72. PubMed ID: 15589564
[TBL] [Abstract][Full Text] [Related]
10. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study.
Skljarevski V; Zhang S; Chappell AS; Walker DJ; Murray I; Backonja M
Pain Med; 2010 May; 11(5):648-57. PubMed ID: 20546509
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
12. Estimation of minimum clinically important difference for pain in fibromyalgia.
Mease PJ; Spaeth M; Clauw DJ; Arnold LM; Bradley LA; Russell IJ; Kajdasz DK; Walker DJ; Chappell AS
Arthritis Care Res (Hoboken); 2011 Jun; 63(6):821-6. PubMed ID: 21312349
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
[TBL] [Abstract][Full Text] [Related]
14. Time course of improvement of different symptom clusters in patients with major depression and pain treated with duloxetine or placebo.
Demyttenaere K; Desaiah D; Petit C; Croenlein J; Brecht S
Curr Med Res Opin; 2012 Jan; 28(1):41-8. PubMed ID: 22126422
[TBL] [Abstract][Full Text] [Related]
15. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain.
Ziegler D; Pritchett YL; Wang F; Desaiah D; Robinson MJ; Hall JA; Chappell AS
Diabetes Care; 2007 Mar; 30(3):664-9. PubMed ID: 17327338
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain.
Skljarevski V; Desaiah D; Zhang Q; Chappell AS; Detke MJ; Gross JL; Ziegler D
Diabetes Metab Res Rev; 2009 Oct; 25(7):623-31. PubMed ID: 19637208
[TBL] [Abstract][Full Text] [Related]
17. The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders.
Farrar JT; Pritchett YL; Robinson M; Prakash A; Chappell A
J Pain; 2010 Feb; 11(2):109-18. PubMed ID: 19665938
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
19. Management of depression relapse: re-initiation of duloxetine treatment or dose increase.
Fava M; Detke MJ; Balestrieri M; Wang F; Raskin J; Perahia D
J Psychiatr Res; 2006 Jun; 40(4):328-36. PubMed ID: 16678205
[TBL] [Abstract][Full Text] [Related]
20. Time course of depression-symptom improvement during treatment with duloxetine.
Hirschfeld RM; Mallinckrodt C; Lee TC; Detke MJ
Depress Anxiety; 2005; 21(4):170-7. PubMed ID: 16035056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
